Business
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZ SAN DIEGO and DUBAI, United Arab Emirates,
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":"Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZ\nSAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Lunatus is an independent pharmaceutical company specialized in the commercialization of pharmaceutical products in the Middle East. Under the terms of the agreement, LENZ will receive upfront, regulatory and commercial milestone payments, in addition to a significant share of revenue generated in the region through a pre-determined minimum product supply price. Lunatus will retain exclusive commercialization rights for VIZZ for the treatment of presbyopia in the Middle East region, including United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon and Iraq. “As the commercial launch of VIZZ in the United States continues to build momentum, we are pleased to expand our network of commercial partnerships in key strategic regions outside the United States. Lunatus represents our fourth commercialization partnership for VIZZ, as we remain deeply committed to expanding global access to this transformative presbyopia therapy,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “Lunatus has built an outstanding reputation in the Middle East for high-quality execution, regulatory excellence and successful commercialization of innovative eye-care products. Their capabilities, combined with the growing unmet need for presbyopia solutions in the Middle East region, make this partnership a powerful fit. We look forward to working together to rapidly bring VIZZ to patients across the region.” “Partnering with LENZ Therapeutics marks an exciting step in expanding access to advanced eye-care solutions in the Middle East region,” said Dr. Lina Kouatly, President & CEO of Lunatus. “VIZZ represents a transformational advancement ...